NC
OTLK icon

NewSquare Capital’s Outlook Therapeutics OTLK Stock Holding History

NewSquare Capital’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10
Closed -$348 – 810
2023
Q2 		$348 Hold
10
– – ﹤0.01% 717
2023
Q1 		$218 Hold
10
– – ﹤0.01% 787
2022
Q4 		$216 Buy
+10
New +$218 ﹤0.01% 725

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

NewSquare Capital's OTLK Position: Q3 2023 in Review

NewSquare Capital sold out of Outlook Therapeutics (OTLK) in Q3 2023, closing a stake of 10 shares — an estimated $348 sold.

NewSquare Capital first reported a position in OTLK in Q4 2022 and held it in 3 quarters. The position peaked at $348 in Q2 2023. 81 funds tracked by Wall St. Rank hold OTLK as of Q3 2023.

  • NewSquare Capital reported no remaining Outlook Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 10 Outlook Therapeutics shares in Q3 2023, an estimated $348.
  • NewSquare Capital first reported a position in Outlook Therapeutics in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Outlook Therapeutics position peaked at $348 in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.